How to Get Lantus in North Dakota

What Is Lantus and Why Is It Prescribed?

Insulin glargine (brand name Lantus) is a long-acting basal insulin analog manufactured by Sanofi and FDA-approved for adults with type 1 or type 2 diabetes requiring basal insulin coverage. It provides a steady, peakless insulin release over approximately 24 hours when injected subcutaneously once daily, typically at bedtime. [1]

The FDA approved the original Lantus formulation in April 2000. The product label specifies a concentration of 100 units per mL (U-100), available in 10 mL vials and 3 mL SoloStar prefilled pens. [1] The standard starting dose for type 2 diabetes is 0.1 to 0.2 units per kg of body weight per day, titrated upward by 2 units every three days until fasting glucose targets are met. [2]

The ORIGIN trial (Outcome Reduction with Initial Glargine Intervention, N=12,537) compared insulin glargine to standard care in people with dysglycemia and established cardiovascular disease or cardiovascular risk factors. Published in the New England Journal of Medicine in 2012, ORIGIN found no significant difference in the primary composite cardiovascular outcome between glargine and standard care over a median of 6.2 years (hazard ratio 1.02; 95% CI 0.94 to 1.11; P=0.63). [3] That finding matters for North Dakota patients, many of whom carry comorbid cardiovascular risk factors alongside diabetes.

The American Diabetes Association 2024 Standards of Care continue to list basal insulin as a cornerstone option for type 2 diabetes intensification when oral agents and GLP-1 receptor agonists are insufficient or not tolerated. [2] Insulin glargine remains the most commonly prescribed basal insulin in the United States. [4]

Who Can Prescribe Lantus in North Dakota?

Any licensed prescriber in North Dakota with DEA registration and authority to prescribe Schedule V or unscheduled drugs may write for insulin glargine. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). North Dakota does not require a supervising physician cosignature for NP or PA insulin prescriptions. [5]

North Dakota Century Code Chapter 43-15 governs pharmacy practice, and Chapter 43-17 governs medicine. North Dakota Board of Nursing rules grant full prescriptive authority to Certified Nurse Practitioners who hold a Certificate of Prescriptive Authority, meaning they can prescribe Schedule IV and below controlled substances and all non-controlled drugs including insulin. [5] PAs in North Dakota prescribe under a delegation agreement with a collaborating physician, but insulin is a non-controlled substance, and most PA practice agreements explicitly cover insulin management. [5]

This broad prescriber base matters for rural North Dakota patients. The state has 53 counties. Roughly 60 percent of North Dakota's population lives in areas classified as rural or frontier. Telehealth closes that gap. [6]

Telehealth Prescribing of Lantus in North Dakota

North Dakota law explicitly permits telehealth prescribing of non-controlled medications, including insulin glargine, without a prior in-person visit when the prescriber establishes a valid patient-physician relationship through a synchronous audio-video encounter. [7]

The state adopted revised telehealth parity rules following the COVID-19 Public Health Emergency. Under North Dakota Administrative Code, telehealth encounters must use two-way, real-time audiovisual technology. Asynchronous store-and-forward messaging alone is insufficient for an initial Lantus prescription. [7]

HealthRX connects North Dakota patients to licensed prescribers via synchronous video visits. A typical workflow: (1) the patient completes an intake form including current medications, A1c history, and blood glucose logs; (2) the prescriber conducts a video visit averaging 20 to 30 minutes; (3) if clinically appropriate, an electronic prescription is transmitted directly to the patient's chosen pharmacy in North Dakota. Most retail chains in the state receive e-prescriptions within minutes of the visit. Patients typically receive their first vial or pen within three to seven days of the initial consult, depending on pharmacy stock and prior authorization requirements.

The HealthRX Telehealth-to-Pharmacy Framework for North Dakota Lantus Access identifies three patient pathways based on insurance status:

Pathway A (Commercial Insurance with formulary coverage): Video visit, e-Rx transmitted, pharmacy verifies benefits, dispenses within 24 to 48 hours. Copay varies by plan tier.

Pathway B (Prior Authorization required): Video visit, e-Rx transmitted with prior authorization packet, insurer review averages 3 to 5 business days in North Dakota per state insurance commissioner data, then dispensing. [8]

Pathway C (Self-pay or ND Medicaid, which does not cover Lantus): Video visit, e-Rx transmitted to preferred pharmacy, patient uses Sanofi Insulins VALu-u-INsulin savings card or manufacturer coupon, or switches to a biosimilar glargine product covered by Medicaid.

What Labs Are Needed Before Getting a Lantus Prescription in North Dakota?

A prescriber will typically review recent lab results before initiating or continuing insulin glargine. The minimum labs recommended by the American Diabetes Association include a hemoglobin A1c, a basic metabolic panel (BMP) for renal function and electrolytes, and a fasting or random blood glucose. [2]

For telehealth visits, patients should have lab results dated within the past 90 days if possible. North Dakota has multiple walk-in lab options including Sanford Health labs in Fargo, Bismarck, and Minot, and Altru Health labs in Grand Forks. Quest Diagnostics and LabCorp both operate patient service centers in Fargo. Results can be uploaded directly to most telehealth portals.

Specific thresholds that affect prescribing decisions: an eGFR below 30 mL/min/1.73 m² warrants dose adjustments and closer monitoring per the FDA label. [1] Patients with an A1c above 10 percent may need concurrent short-acting insulin in addition to basal glargine. The ADA recommends an A1c target of below 7 percent for most non-pregnant adults, or below 8 percent for those with hypoglycemia unawareness, limited life expectancy, or significant comorbidities. [2]

No North Dakota state regulation requires specific labs before insulin prescribing. The lab requirements come from clinical best practice and insurer prior authorization criteria, not from state law. [5]

How Prior Authorization Works for Lantus in North Dakota

Most commercial and managed care plans in North Dakota require prior authorization (PA) for Lantus because lower-cost biosimilar glargine products (including Basaglar, Semglee, and Rezvoglar) are available. [9] The PA process asks the prescriber to document:

1. Confirmed diagnosis of type 1 or type 2 diabetes with an ICD-10 code (E10.x or E11.x)
2. Current A1c and recent fasting glucose readings
3. History of previous insulin therapy and any therapeutic failures or intolerances
4. Clinical justification if Lantus specifically is requested over a biosimilar

North Dakota does not have a state law mandating automatic approval of insulin prior authorizations within a set timeframe for commercial plans, though the North Dakota Insurance Department enforces federal timelines: non-urgent PA decisions within 72 hours for concurrent or retrospective reviews, and 15 calendar days for standard prospective requests. [8]

Blue Cross Blue Shield of North Dakota, the state's largest insurer, lists insulin glargine products on its formulary with step therapy requirements. Sanford Health Plan and Medica also operate in the state. Each has slightly different step therapy protocols. HealthRX prescribers submit PA documentation directly through CoverMyMeds, the most widely used PA platform accepted by North Dakota pharmacies.

Patients on North Dakota Medicaid should be aware that Lantus (branded insulin glargine 100 units/mL) is not covered under the standard ND Medicaid drug program for most beneficiaries. The ND Medicaid Preferred Drug List does cover some biosimilar or alternative basal insulin products. Patients should ask their prescriber about switching to a covered formulary agent, or apply for Sanofi's patient assistance program (Insulins VALu-u-INsulin), which caps out-of-pocket costs at a set monthly amount for eligible patients. [10]

Lantus Pharmacies in North Dakota

All major retail pharmacy chains operating in North Dakota stock insulin glargine, including Lantus vials and SoloStar pens. Pharmacy chains with North Dakota locations include Walgreens, CVS, Walmart Pharmacy, and Thrifty White Pharmacy (a regional chain with strong North Dakota presence). Hospital-affiliated outpatient pharmacies at Sanford Health and CHI St. Alexius also dispense Lantus. [11]

For patients in rural or frontier counties, mail-order pharmacy is often the most practical option. Express Scripts, OptumRx, and Walgreens Mail are the three most common pharmacy benefit managers with mail-order programs accepted by North Dakota insurers. Mail-order dispensing typically provides a 90-day supply at a lower per-unit cost than retail. [11]

503A compounding pharmacies licensed in North Dakota may prepare insulin glargine formulations for patients with documented medical needs that cannot be met by commercially available products, such as a specific concentration, preservative-free formulation, or delivery device accommodation. 503A pharmacies must comply with North Dakota Board of Pharmacy rules and USP Chapter 797 sterile compounding standards. [12] Compounded insulin glargine is not therapeutically equivalent to FDA-approved Lantus and is not interchangeable at the pharmacy counter.

Insulin glargine biosimilars that are FDA-designated interchangeable with Lantus include Semglee (insulin glargine-yfgn, Viatris) and Rezvoglar (insulin glargine-aglr, Eli Lilly). Interchangeable biosimilars may be substituted by a pharmacist in North Dakota without prescriber intervention unless the prescriber specifies "dispense as written." [9] Patients who want brand-name Lantus specifically should ask their prescriber to note "DAW" on the prescription.

How to Transfer an Existing Lantus Prescription to North Dakota

Patients relocating to North Dakota or establishing a new care relationship in the state can transfer a Lantus prescription from another state pharmacy to a North Dakota pharmacy, subject to these conditions:

First, insulin glargine is a non-controlled substance. North Dakota pharmacy law permits transfer of non-controlled prescriptions between pharmacies licensed in any state. [5] The receiving pharmacy contacts the originating pharmacy directly; the patient does not need to take any action beyond requesting the transfer.

Second, if the original prescription has zero refills remaining, a new prescription from a North Dakota-licensed prescriber is required. Telehealth providers can issue a new prescription after a brief medication review visit. Lab results from another state are acceptable for this review; the prescriber does not need to repeat labs if results are recent and complete.

Third, some insurers require that prescription fills originate from in-network pharmacies in the patient's state of residence. A patient who moves to North Dakota should notify their insurer and update their pharmacy benefit accordingly.

The transfer process at a retail chain pharmacy (Walgreens to Walgreens, for example) is typically completed within two to four hours same-day. Cross-chain transfers may take 24 hours if telephone verification between pharmacies is required. [11]

Dosing and Administration: What Patients in North Dakota Need to Know

Lantus is injected subcutaneously. Approved injection sites are the abdomen, thigh, and upper arm. The prescriber or pharmacist will typically demonstrate injection technique at the first dispensing or via a telehealth video. Rotating injection sites within the same anatomical region is recommended to prevent lipohypertrophy. [1]

The FDA label specifies that Lantus must never be diluted or mixed with other insulins or solutions. Mixing Lantus in the same syringe with rapid-acting insulin (such as lispro or aspart) is contraindicated because mixing alters the pharmacokinetic profile of both insulins and may cause erratic glycemic control. [1]

Hypoglycemia is the most common adverse effect. The ORIGIN trial reported a severe hypoglycemia rate of 1.00 events per 100 person-years in the glargine group versus 0.31 events per 100 person-years in the standard care group over 6.2 years. [3] Patients should keep fast-acting glucose (glucose tablets, 4 ounces of juice) accessible at all times. The ADA defines severe hypoglycemia as a blood glucose below 54 mg/dL or any episode requiring assistance from another person. [2]

Weight gain is a known effect of basal insulin therapy. In ORIGIN, patients in the glargine arm gained a mean of 1.6 kg compared to a 0.5 kg loss in the standard care arm at the end of the trial. [3] For patients concerned about weight gain, the ADA 2024 guidelines recommend discussing GLP-1 receptor agonist combination therapy, which can mitigate insulin-associated weight gain. [2]

Storage and Handling in North Dakota's Climate

North Dakota winters are severe. Insulin glargine freezes at approximately 32 degrees Fahrenheit, and frozen insulin is destroyed and must be discarded. [1] Patients transporting insulin in vehicles during winter should keep vials in an insulated bag with a temperature indicator. Insulin should never be stored in a car glove box or trunk in temperatures below 32 degrees or above 77 degrees Fahrenheit.

Unopened Lantus vials and pens should be refrigerated between 36 and 46 degrees Fahrenheit until the expiration date printed on the label. [1] Once opened (first use), a vial may be stored at room temperature (below 77 degrees F) for up to 28 days. An opened SoloStar pen should be stored unrefrigerated for up to 28 days. [1]

During North Dakota power outages, which can accompany blizzards, patients should use a cooler with ice packs to keep insulin between 36 and 46 degrees. The North Dakota Department of Health recommends that patients with insulin-dependent diabetes register with their local emergency management office to receive priority notification during power outage events. [6]

Cost of Lantus in North Dakota Without Insurance

The retail cash price for a 10 mL vial of Lantus (1,000 units) at North Dakota pharmacies ranges from approximately $290 to $340 per vial as of 2025, depending on the pharmacy. A typical type 2 diabetes patient on 30 units per day would use approximately one vial every 33 days, making the uninsured annual cost around $3,200 to $3,700. [10]

Cost reduction options available to North Dakota residents:

Sanofi Insulins VALu-u-INsulin: Sanofi's savings program caps Lantus costs for eligible commercially insured patients. Uninsured patients may qualify for zero-dollar or reduced-cost insulin through Sanofi's Patient Connection program. [10]

GoodRx and similar discount cards: GoodRx pricing at Walmart Pharmacy in Fargo has been as low as $165 for a 10 mL vial of Lantus with a coupon code, though prices fluctuate weekly. These coupons cannot be used with insurance.

Biosimilar switch: Semglee (insulin glargine-yfgn) carries a significantly lower list price than branded Lantus. At many North Dakota pharmacies, Semglee cash price is approximately 65 to 85 percent of the Lantus list price. [9]

ReliOn Insulin at Walmart: ReliOn brand insulin (NPH and Regular, not glargine) is available over the counter in North Dakota at Walmart for $25 per vial. NPH is not therapeutically equivalent to insulin glargine and requires twice-daily dosing; switching insulin types requires prescriber oversight. [4]

The American Diabetes Association's 2024 insulin access position statement notes that insulin affordability remains a significant barrier in the United States, with approximately 1.3 million adults rationing insulin due to cost, a practice associated with increased diabetic ketoacidosis hospitalization rates. [2]

Starting the Process Today

Patients in North Dakota can book a telehealth video visit with a HealthRX-affiliated prescriber licensed in North Dakota through the HealthRX patient portal. Have your most recent A1c result (dated within 90 days), a list of current medications, and your pharmacy's name and address ready before the visit. If labs are not current, request a same-day lab order during the visit and proceed to a local draw site. Most North Dakota patients who complete the intake form and video visit before noon on a business day receive an electronic prescription by end of day and can pick up their Lantus within 24 to 48 hours at an in-network pharmacy.